These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 35076721)
21. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. Leger RF; Unterwald EM J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567 [TBL] [Abstract][Full Text] [Related]
23. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. Leonard JB; Anderson B; Klein-Schwartz W J Psychopharmacol; 2018 Dec; 32(12):1286-1294. PubMed ID: 30182795 [TBL] [Abstract][Full Text] [Related]
24. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281 [TBL] [Abstract][Full Text] [Related]
25. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790 [TBL] [Abstract][Full Text] [Related]
26. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. Schmid Y; Gasser P; Oehen P; Liechti ME J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422 [TBL] [Abstract][Full Text] [Related]
27. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Lea T; Amada N; Jungaberle H; Schecke H; Klein M Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967 [TBL] [Abstract][Full Text] [Related]
28. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231 [TBL] [Abstract][Full Text] [Related]
29. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460 [TBL] [Abstract][Full Text] [Related]
31. Long-lasting subjective effects of LSD in normal subjects. Schmid Y; Liechti ME Psychopharmacology (Berl); 2018 Feb; 235(2):535-545. PubMed ID: 28918441 [TBL] [Abstract][Full Text] [Related]
32. LSD-associated "Alice in Wonderland Syndrome"(AIWS): A Hallucinogen Persisting Perception Disorder (HPPD) Case Report. G Lerner A; Lev-Ran S Isr J Psychiatry Relat Sci; 2015; 52(1):67-8. PubMed ID: 25841113 [TBL] [Abstract][Full Text] [Related]
33. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Baggott MJ; Coyle JR; Erowid E; Erowid F; Robertson LC Drug Alcohol Depend; 2011 Mar; 114(1):61-7. PubMed ID: 21035275 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic Applications of Classic Hallucinogens. Bogenschutz MP; Ross S Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684 [TBL] [Abstract][Full Text] [Related]
35. The use of classic psychedelics among adults: a Danish online survey study. Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202 [TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation. Lev-Ran S; Feingold D; Frenkel A; Lerner AG J Dual Diagn; 2014; 10(2):79-83. PubMed ID: 25392249 [TBL] [Abstract][Full Text] [Related]